-
Study Exposes Dangerous and Possibly Deadly Risk of Bleeding From Pradaxa
Go to Study Exposes Dangerous and Possibly Deadly Risk of Bleeding From PradaxaIn addition to risks of hemorrhaging associated with taking Pradaxa, a study published in the January 9, 2012 issue of Archives of Internal Medicine reports that patients taking Pradaxa (dabigatran) have a 33% greater chance of developing heart disease or experiencing cardiac arrest. Currently, Pradaxa is being investigated by the Food and Drug Administration. Even…
-
Pradaxa Has Risk of Irreversible Bleeding
Go to Pradaxa Has Risk of Irreversible BleedingPradaxa was approved by the U.S. Food and Drug Administration (FDA) in October of 2010. However, since that time, medical professionals have become increasingly alarmed about irreversible bleeding that can occur in patients taking the blood thinner Pradaxa (generic name dabigartran). The FDA has been reviewing the drug since December of 2011, because of these…
